Edgewise Therapeutics Q4 net loss widens vs Q3 as costs rise
Overview
Muscle disease biopharma's Q4 net loss widens from Q3 to $50.2 mln, with increased operating expenses
Company's R&D expenses rose due to personnel and clinical trial costs
Edgewise advances muscular dystrophy and cardiovascular programs with key trials in 2026
Outlook
Edgewise expects CIRRUS-HCM 12-week data for EDG-7500 in H1 2026
Company plans Phase 3 trial initiation for EDG-7500 in HCM in H2 2026
Edgewise anticipates GRAND CANYON trial data in Becker in Q4 2026
Result Drivers
R&D EXPENSES - Increase driven by personnel costs and clinical trial activities for EDG-15400 and EDG-7500
MUSCULAR DYSTROPHY PROGRAM - Advancing trials for sevasemten in Becker and Duchenne muscular dystrophies
CARDIOVASCULAR PROGRAMS - Progressing CIRRUS-HCM and EDG-15400 trials with key data expected in 2026
Company press release: ID:nPn4QbXrwa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Income |
| -$50.22 mln |
|
Q4 Basic EPS |
| -$0.47 |
|
Q4 Operating Expenses |
| $55.98 mln |
|
Q4 Operating Income |
| -$55.98 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Edgewise Therapeutics Inc is $41.50, about 37.8% above its February 25 closing price of $30.12
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
Has Beating Expectations Become the Norm? Nvidia Delivers Strong Q4 Results Again, but Market Remains Cautious?
TradingKey - Nvidia (NVDA) reported fourth-quarter results on Wednesday that beat expectations across the board, with its core data center business revenue surging 75% year-over-year to become the primary growth engine.
Circle Stock Price Outlook: Will Circle Internet Group Rebound in 2026?
TradingKey - Circle Internet Group (CRCL) saw its stock price experience a roller coaster ride since its 2025 IPO debut at $31 a share. Those early fireworks faded, and the shares now sit roughly 75% below their June peak, though they’re still more than double the IPO level. Outside of that first-mo
Nvidia Q4 Earnings: Market Fears Competition, but NVDA Moat is Beyond CUDA
All eyes are on Nvidia this week, as the company reports its 2026Q4 earnings.
Nvidia Q4 Earnings Preview: AI-Driven Growth Versus Market Expectations
TradingKey - NVIDIA (NVDA) is set to release its fourth quarter fiscal year 2026 earnings report after the market close on February 25, ET. As the world undergoes a period of rapid AI technological advancement, market debates over a capital expenditure bubble have intensified. In this context, NVIDIA’s results serve not only as a test of its business performance but also as a core bellwether for the sustainability of the global AI boom.
